The pharmacological treatment options in schizophrenia developing resistance to clozapine are limited. Few studies have found ECT as beneficial in TRS, including CRS. However, literature on the role of M-ECT in maintaining the therapeutic gains of acute ECT in CRS is lacking. The objective of the study is to compare the efficacy of M-ECT vs aripiprazole as an add-on to ongoing clozapine on the severity of symptom dimensions, cerebral perfusion, global functioning and cognitions in patients with CRS.
Patients clinically diagnosed with CRS (currently under clozapine)
Patients aged 18-60 years of either sex.
LAR giving voluntary written consent for participation in the study
Patient already on ECT or aripiprazole.
History of psychoactive substance abuse or dependence.
Co-morbid psychiatric, major medical or neurological disorders.
History of organicity or significant head injury.